Todays NEJM: Ruxolitinib effective in glucocorticoid-refractory Chronic Graft-versus-Host Dz. Phase 3, 329 pts; wk 24 responses better w/ RUX (50 vs 26%; P<0.001). Important? as there is phase 2 data showing JAK efficacy in scleroderma https://t.co/ygLevqfuMW